БЛОГ

Sep 8, 2022

Elon Musk’s NEURALINK vs Bryan Johnson’s KERNEL (No Surgery)

Posted by in categories: biotech/medical, Elon Musk, life extension, neuroscience, robotics/AI, wearables

00:00 Intro.
02:44 Kernel Flow brain interface.
08:03 Seeing my brain activity.
12:42 Reversing aging-Project Blueprint.
18:18 Overcoming depression.
26:42 Starting Kernel.
34:40 Why non-invasive?
36:43 Comparison to Tesla/ Neuralink.
43:52 Elon considered joining Kernel?
44:52 Kernel hiring.
46:17 Participate in the studies.

Participate & experience Kernel Flow: https://www.kernel.com/participate.
Information: Kernel Flow: https://www.kernel.com/flow.
Kernel Careers: https://jobs.lever.co/kernel-2
Neura Pod Episode about Kernel & Bryan Johnson: https://youtu.be/c0VFiEhDg6I
Bryan Johnson LinkedIn: https://www.linkedin.com/in/bryanrjohnson/
Bryan Johnson Personal Page: https://www.bryanjohnson.co/
Blueprint Website: https://blueprint.bryanjohnson.co/

After selling his company, Braintree/Venmo, for $800 million and battling chronic depression for 10 years, Bryan Johnson is now on a mission to help us measure and gather more data about the organ that makes us oh-so human: our brain.

In this episode, Ryan Tanaka and Omar Olivares share an exclusive, behind the scenes look of Kernel’s headquarters near Los Angeles, California. Ryan interviews Bryan Johnson, tries on Kernel’s wearable brain-interface, ‘Flow,’ and learns about the engineering and technology developments needed to make it all happen. CTO, Ryan Field and Director of Applied Neuroscience, Katherine Perdue also share insights about Kernel’s wearable Flow headset.

Disclaimer: Thanks to Kernel for opening their office for us to film in and for supporting our travel and accommodation.

Neura Pod is a series covering topics related to Neuralink, Inc. Topics such as brain-machine interfaces, brain injuries, and artificial intelligence will be explored. Host Ryan Tanaka synthesizes informationopinions, and conducts interviews to easily learn about Neuralink and its future.

Comments are closed.